European Journal of Plastic Surgery

, Volume 14, Issue 4, pp 200–202 | Cite as

A case of prolonged allograft survival after a short-term treatment with cyclosporin A in a child with aplastic anemia

  • S. Lusthaus
  • T. Kaufman
  • A. Livoff
  • MR Wexler
Case Reports
  • 17 Downloads

Summary

A child with severe idiopathic aplastic anemia was treated with cyclosporin A for 16 weeks. Skin necrosis occurred on the dorsum of the left hand; mucormycosis was cultured. An underlying osteomyelitis was suspected. The defect was covered with live donor allograft skin, since it was feared that there would be considerable bleeding from autograft donor sites. There was no evidence of graft rejection, either during treatment or in the year after cyclosporin A was withdrawn. No evidence of mucormycosis or osteomyelitis was seen subsequent to skin grafting.

Key words

Aplastic anemia Cyclosporin A Immunosuppression Long-term allograft tolerance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Achauer BM, Black KS, Hewit CW, Furnas DW (1985) Immunosurgery. Clin Plast Surg 12:293–307Google Scholar
  2. 2.
    Achauer BM, Black KS, Furnas DW et al. (1986) Longterm skin allograft survival after short-term cyclosporin treatment in a patient with massive burns. Lancet 4:14–15Google Scholar
  3. 3.
    Achauer BM, Hewit CW, Black KS et al (1983) Cyclosporin prolongs skin allograft in a rat burn model. Transplant Proc 15:3073Google Scholar
  4. 4.
    Binford H, Dooley J (1976) Pathology of tropical and extraordinary disease. In: Binford CH, Connor DH (eds) AFIP, Washington, DC, Vol II, Sec 13, Chap 1, 564–565Google Scholar
  5. 5.
    Cosimi AB, Shield CF, Peters C et al (1979) Prolongation of allograft rejection by cyclosporin A. Surg Forum 30:287Google Scholar
  6. 6.
    Gartenberg G, Bottone EJ, Keusch GT, Weitzman I (1978) Hospital acquired mucormycosis of skin and subcutaneous tissue. N Engl J Med 299:1115–1118Google Scholar
  7. 7.
    Homan WP, Fabre JW, Williams KA et al (1980) Studies on the immunosuppressive properties of cyclosporin A in rats receiving renal allografts. Transplantation 29:361Google Scholar
  8. 8.
    Kostakis AJ, Withe DJ, Calne RY (1977) Prolongation of heart rat allograft survival by cyclosporin A. IRCS J Med Sci 5:280Google Scholar
  9. 9.
    Kupiec-Weglinski JW, Filho MA, Strom TB, Tilney NL (1984) Sparing of suppressor cells; a critical action of cyclosporin. Transplantation 38:97–101Google Scholar
  10. 10.
    Kramer BS, Hernandez AD, Reddick MD, Levine AS (1977) Infarction: manifestation of disseminated mucormycosis. Arch Dermatol 113:1075–1076Google Scholar
  11. 11.
    Lafferty KJ, Prowse SJ, Simeonovic CJ (1983) Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Ann Rev Immunol 1:143–173Google Scholar
  12. 12.
    Morris PJ (1984) The impact of cyclosporin A on transplantation. Adv Surg 17:99–127Google Scholar
  13. 13.
    Opelz G, Sengar DPS, Micket MR et al (1973) Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 4:253–259Google Scholar
  14. 14.
    Roberts HJ (1962) Cutaneous mucormycosis. Arch Intern Med 110:108–112Google Scholar
  15. 15.
    Towpik E, Kupiec-Weglinski JW, Tyler DS, Araujo JL et al (1985) Cyclosporin and experimental allografts: long-term survival in rats treated with low maintenance doses. Plast Reconstr Surg 77:268–273Google Scholar
  16. 16.
    Towpik E, Kupiec-Weglinski JW, Tilney NL (1985) The potential use of cyclosporin in reconstructive surgery. Plast Reconstr Surg 76:312–322Google Scholar
  17. 17.
    Ward FE, Mendell NR, Seigler HF et al (1978) Factors which have a significant effect on the survival of human skin grafts. Transplantation 26:194–198Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • S. Lusthaus
    • 1
  • T. Kaufman
    • 1
  • A. Livoff
    • 2
  • MR Wexler
    • 1
  1. 1.Department of Plastic and Maxillofacial Surgery and Burn UnitHadassah Medical Organization, University HospitalJerusalemIsrael
  2. 2.Department of PathologyHadassah Medical Organization, University HospitalJerusalemIsrael

Personalised recommendations